Table 1.

The clinical importance of STC2 in human cancers

Tumours	Patient Numbers	Detection Methods	Clinical Importance
Breast cancer	110	qRT-PCR	Elevated STC2 mRNA levels are correlated with higher DFS rates [50]
	245	FISH	STC2 expression is associated with improved DFS rates [51]
	110	IHC	No relationship with progression free survival is demonstrated [52]
	985 + 979	Microarray	STC2 levels are correlated with good prognosis [53]
	699	IHC	No correlation is revealed between STC2 levels and tumour recurrence [54]
	477	IHC	STC2 is associated with favorable outcome in male breast cancer patients [55]
Colorectal cancer	139	qRT-PCR	High STC2 levels are correlated with poor prognosis [33]
	47	qRT-PCR	STC2 expression is associated with tumour size [56]
	77	IHC	STC2 levels are correlated with tumour stage and patients’ survival [57]
	383	Microarray	STC2 expression is associated with tumour stages [58]
	115	IHC	STC2 levels are correlated with tumour metastasis and disease stages [59]
	379	RNA-Seq	Elevated STC2 expression is associated with poor prognosis [60]
	202	qRT-PCR	High STC2 mRNA expression is correlated with poor postoperative survival [61]
Gastric cancer	108	qRT-PCR	STC2 mRNA levels are higher in cancer than those in normal gastric mucosa, and associated with tumour progression and poor prognosis [62]
	93	qRT-PCR	Blood STC2 levels are correlated with tumour progression and poor prognosis [63]
ESCC	70	qRT-PCR	Elevated STC2 mRNA levels are associated with lymph node metastasis and poor prognosis [35]
Prostate cancer	53	IHC	STC2 IHC staining score is correlated with high Gleason scores [36]
RCC	108	IHC	For all RCC, clear cell RCC, papillary RCC, patients with high cytosolic STC2 staining have a poor prognosis than those with low expression [37]
Nasopharyngeal carcinoma	94	IHC	Overall survival rate of patients with high STC2 levels is significantly lower than those with low STC2 expression [38]
	62	IHC	STC2 is a valuable prognostic marker for poor outcome [64]
	81	IHC	STC2 positive patients show poor outcome [65]
	111	RNA-Seq	STC2 is regarded as a biomarker for evaluating patients’ prognosis [66]
	68	IHC	STC2 expression is associated with poor progression [67]
	111	RNA-Seq	STC2 can be applied to predict the overall survival rates of patients [68]
HNSCC	298	IHC	Elevated STC2 expression is correlated with poor outcome [39]
	119	IHC	High STC2 expression is significantly associated with poor survival [69]
	498	RNA-Seq	High STC2 levels are correlated with poor prognosis [70]
HCC	240	IHC	STC2 expression is associated with poor survival [40]
	200	IHC	High STC2 is correlated with poor prognosis [71]
	258	IHC	High STC2 expression can be utilized to predict overall survival [72]
	364	RNA-Seq	STC2 expression is associated with poor prognosis of HCC [73]
Osteosarcoma	88	RNA-Seq	STC2 has an important influence on the survival of patients [41]
	88	RNA-Seq	STC2 is correlated with the patients’ prognosis and metastasis [74]
	87	RNA-Seq	Elevated STC2 levels are associated with poor prognosis [75]
Ovarian cancer	46	qRT-PCR	Overexpression of STC2 by vascular cells in ovarian cancer is correlated with decreased disease-free interval [42]
	278	IHC	STC2 is associated with tumour grade, tumour histotype and poor overall survival [76]
Lung cancer	115	IHC	STC2 mediates the resistance to EGFR tyrosine kinase inhibitors [43]
Pancreatic Cancer	98	qRT-PCR	STC2 expression is correlated with clinicopathological factors and patients’ prognosis [44]
Endometrial cancer	49	IHC	High STC2 expression is associated with poor relapse-free survival [45]
Cervical cancer	92	IHC	STC2 expression is correlated with shorter survival [46]
Neuroblastoma	50	qRT-PCR	STC2 mRNA levels are associated with higher clinical stages [47]
Gallbladder cancer	46 + 80	IHC	STC2 expression is correlated with clinical, pathological, and biological behaviors as well as poor prognosis of gallbladder cancer [48]
Cholangiocarcinoma	100	IHC	Positive expression of STC2 is associated with progression and poor clinical outcomes [49]